CellWell record HH-100887
Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
Ip S; North TL; Torabi F; Li Y; Abbasizanjani H; Akbari A; Horne E; Denholm R; Keene S; Denaxas S; Banerjee A; Khunti K; Sudlow C; Whiteley WN; Sterne JAC; Wood AM; Walker V; CVD-COVID-UK/COVID-IMPACT Consortium; Longitudinal Health and Wellbeing COVID-19 National Core Study
Nature communications ยท 2024
In plain language
A cohort study of 46 million adults in England found lower arterial and venous thrombotic event rates after COVID-19 vaccination, alongside higher rates of rare harms including thrombotic thrombocytopenia after first ChAdOx1 doses and myocarditis or pericarditis after mRNA doses.
- Evidence
- Emerging
- Design
- Cohort study
Cite this record: https://thecellwell.org/studies/HH-100887
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.